Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,526JPY
1:00am EST
Change (% chg)

¥-4 (-0.23%)
Prev Close
¥1,530
Open
¥1,512
Day's High
¥1,526
Day's Low
¥1,507
Volume
11,481,900
Avg. Vol
7,470,428
52-wk High
¥1,798
52-wk Low
¥1,358

Latest Key Developments (Source: Significant Developments)

Astellas to acquire Ganymed Pharmaceuticals 422 mln euros
Friday, 28 Oct 2016 09:00am EDT 

Astellas Pharma Inc <4503.T> : Astellas to acquire ganymed pharmaceuticals . Atellas will pay eur 422 million to acquire 100% of equity in Gnymed . Gnymed's shareholders to become eligible to receive up to eur 860 million in further contingent payments based on progress in development of imab362 .Is still reviewing impact of this transaction on its financial forecasts for fiscal year ending March 31, 2017.  Full Article

Astellas to buy Ganymed Pharmaceuticals for 422 mln euros
Thursday, 27 Oct 2016 11:00pm EDT 

Astellas Pharma Inc <4503.T>: Astellas says to buy Ganymed Pharmaceuticals for EUR 422 million ($460 million) .Astellas says to pay up to EUR 860 million in contingent payments depending on progress in development of Ganymed's IMAB362.  Full Article

R&I affirms Astellas Pharma's rating at "AA" and says stable outlook – R&I
Thursday, 8 Sep 2016 02:00am EDT 

Astellas Pharma Inc <4503.T>: Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA" – R&I .Rating outlook stable– R&I.  Full Article

Astellas Pharma to create companion diagnostic for acute Myeloid Leukemia treatment-Nikkei<4503.T>
Monday, 15 Aug 2016 03:39pm EDT 

Nikkei: Astellas Pharma to create with U.S. co so-called companion diagnostic for acute myeloid leukemia treatment the co has been working on-Nikkei . Astellas Pharma seeks to obtain approval in Japan, U.S. and elsewhere within three years-Nikkei .  Full Article

Astellas Pharma submits new drug application for extended-release tablets of quetiapine fumarate in Japan
Tuesday, 9 Aug 2016 02:00am EDT 

Astellas Pharma Inc <4503.T>: Says it submitted a new drug application to the Ministry of Health, Labour and Welfare in Japan for extended-release tablets of quetiapine fumarate for the indication of improvement of depressive symptoms associated with bipolar disorder .Says it has a license agreement with AstraZeneca UK Ltd. that provides the co exclusive rights to develop and commercialize extended-release tablets of quetiapine fumarate in Japan.  Full Article

Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration
Monday, 8 Aug 2016 10:57am EDT 

Proteostasis Therapeutics Inc : Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration . Says milestone demonstrated selective modulation of UPR pathway in vitro . Says milestone triggered an undisclosed payment from Astellas . Astellas retains right to begin 2 additional projects, which, if fully exercised would bring potential value of collaboration to $1.2 billion .As a result of preclinical milestone, co eligible for further milestone payments, which could result in total payments of over $400 million.  Full Article

DigiTx Partners says raised about $10.5 mln in equity financing
Thursday, 4 Aug 2016 12:35pm EDT 

Digitx Partners Llc : Digitx Partners LLC says it raised about $10.5 mln in equity financing of the total offering amount of $21 mln - SEC .  Full Article

Astellas Pharma unit to sell Astellas Pharma Technologies to Avara
Thursday, 4 Aug 2016 02:00am EDT 

Astellas Pharma Inc <4503.T>: Says its unit to sell Astellas Pharma Technologies, Inc. to Avara Norman Pharmaceutical Services, Inc (Avara) on Aug. 4 (U.S time) .Says transaction price is not disclosed.  Full Article

Astellas to transfer U.S. manufacturing unit to Avara
Wednesday, 3 Aug 2016 08:52pm EDT 

Astellas Pharma Inc <4503.T> : Astellas announces transfer of U.S. manufacturing subsidiary to Avara . Under terms of transaction, APT employees will remain employed at site .Astellas Pharma Technologies, Inc. will be renamed Avara Pharmaceutical Technologies, Inc.  Full Article

Astellas to transfer U.S. manufacturing unit to Avara<4503.T>
Wednesday, 3 Aug 2016 07:00pm EDT 

Astellas Pharma Inc <4503.T> : Astellas announces transfer of U.S. manufacturing subsidiary to Avara . Under terms of transaction, APT employees will remain employed at site .Astellas Pharma Technologies, Inc. will be renamed Avara Pharmaceutical Technologies, Inc.  Full Article

BRIEF-Astellas to acquire Ganymed Pharmaceuticals 422 mln euros

* Atellas will pay eur 422 million to acquire 100% of equity in Gnymed